Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dermata Therapeutics ( (DRMA) ) has issued an announcement.
On May 14, 2025, Dermata Therapeutics received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement, risking delisting. The company was granted an exception until August 14, 2025, to regain compliance, and is seeking shareholder approval for a reverse stock split to meet Nasdaq’s requirements.
The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of dermatology treatments. The company is engaged in creating innovative therapies for skin diseases, aiming to address unmet medical needs in the dermatological market.
Average Trading Volume: 153,230
Technical Sentiment Signal: Sell
Current Market Cap: $4.24M
For a thorough assessment of DRMA stock, go to TipRanks’ Stock Analysis page.